Side-by-side · Research reference

EpitalonvsGlutathione

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED8/37 cited

BHuman-MechanisticHUMAN-REVIEWED6/39 cited

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

Glutathione

Endogenous Tripeptide · Antioxidant

γ-Glu-Cys-GlyStructure

UbiquitousTissue distribution

GCL + GSBiosynthesisWang 2026 Aiana 2026

IV · Oral · Inhaled

01Mechanism of Action

Parameter

Epitalon

Glutathione

Primary target

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

Intracellular redox systems, glutathione peroxidase, glutathione transferase

Pathway

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

Synthesized via glutamate-cysteine ligase (GCL) → γ-glutamylcysteine → glutathione synthetase (GS) → GSH

Downstream effect

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

Reduction of reactive oxygen species, conjugation of electrophiles, maintenance of cellular thiol-disulfide balance, GPX4 activation for lipid peroxide reduction

Feedback intact?

—

Origin

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

Endogenous tripeptide; predominantly synthesized in liver, exported to extracellular space and tissuesTerrell 2025 Hecht 2026

Antibody development

—

02Dosage Protocols

Parameter

Epitalon

Glutathione

Standard dose

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

—

Frequency

Once daily during a cycle

—

Lower / starter dose

2.5 mg / day

—

Evidence basis

In-vitro telomerase + Russian clinical trialsKhavinson 2003

Animal mechanistic + human mechanistic

Duration

10–20 day cycles, 1–2× per year

—

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep preferred (pineal alignment)

—

Half-life

Hours (estimated)

—

Endogenous synthesis

—

Hepatic synthesis ~10 g/day (basal rate)

Tissue-specific; demand-driven upregulation via Nrf2 signaling.

Exogenous oral

—

250–1000 mg/day

Bioavailability limited; gastric hydrolysis reduces systemic uptake.

IV supplementation

—

600–1200 mg (research protocols)

Used in clinical oxidative stress and hepatic detoxification studies.

Precursor strategy

—

N-acetylcysteine (NAC) 600–1200 mg/day

Provides cysteine for endogenous GSH synthesis; bypasses GI degradation.

04Side Effects & Safety

Parameter

Epitalon

Glutathione

Injection site reaction

Mild irritation

—

Sleep architecture

Improved subjective sleep quality (anecdotal)

—

Cancer risk

Theoretical via telomerase activation in pre-malignant cells

—

Long-term safety

Limited Western RCT data

—

Pregnancy / OB

Avoid

—

Antibody formation

Not reported

—

Oral supplementation

—

GI discomfort, bloating (mild, dose-dependent)

IV administration

—

Rare hypersensitivity, infusion site reaction

Inhalation

—

Bronchospasm risk in asthma (rare)

Tumor metabolism

—

Extracellular GSH catabolism supplies cysteine to tumors; theoretical concern in active malignancyHecht 2026

Absolute Contraindications

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

Glutathione

—

Relative Contraindications

Epitalon

·Family history of cancer

Glutathione

·Active malignancy (theoretical cysteine supply risk)Hecht 2026
·Severe asthma (inhaled formulations)

05Administration Protocol

Parameter

Epitalon

Glutathione

1. Reconstitution

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

Capsule or liquid form, 250–1000 mg once daily. Take on empty stomach for improved absorption, though GI hydrolysis limits bioavailability. NAC precursor strategy often preferred.

2. Injection site

SQ — abdomen preferred. Rotate sites.

Clinical protocols: 600–1200 mg slow infusion over 30–60 minutes. Used for acute oxidative stress, hepatic detoxification support. Administered in medical settings.

3. Timing

Pre-sleep preferred to align with pineal axis.

Nebulized GSH (research protocols). Monitor for bronchospasm in reactive airway patients. Used experimentally for pulmonary oxidative stress.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

N-acetylcysteine (NAC) 600–1200 mg/day PO. Provides cysteine substrate for endogenous GSH synthesis. Bypasses gastric degradation, preferred for chronic supplementation.

5. Needle

29–31G, 4–8 mm insulin syringe.

—